From autoinflammation to autoimmunity: old and recent findings

1.

Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668PubMedPubMedCentralCrossRef

2.

de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P (2017) The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 8:43PubMedPubMedCentral

3.

McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297PubMedPubMedCentralCrossRef

4.

Ombrello MJ (2015) Advances in the genetically complex autoinflammatory diseases. Semin Immunopathol 37:403–406PubMedPubMedCentralCrossRef

5.

Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161PubMedCrossRef

6.

Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A (2013) Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review. Clin Rev Allergy Immunol 45:227–235PubMedCrossRef

7.

Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L, Ghirardello A, Iaccarino L, Punzi L (2012) Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 12:22–30PubMedCrossRef

8.

Borella E, Palma L, Zen M, Bettio S, Nalotto L, Gatto M, Domeneghetti M, Iaccarino L, Punzi L, Doria A (2014) The body against self: autoinflammation and autoimmunity. Isr Med Assoc J 16:608–610PubMed

9.

Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350PubMedCrossRef

10.

Shi G, Zhang J, Zhang ZJ, Zhang X (2015) Systemic autoimmune diseases 2014. J Immunol Res 2015:183591

11.

Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426PubMedCrossRef

12.

Theofilopoulos AN, Gonzalez-Quintial R, Lawson BR, Koh YT, Stern ME, Kono DH, Beutler B, Baccala R (2010) Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol 6:146–156PubMedPubMedCentralCrossRef

13.

Vajjhala PR, Ve T, Bentham A, Stacey KJ, Kobe B (2017) The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways. Mol Immunol 86:23–37PubMedCrossRef

14.

McGonagle D, Savic S, McDermott MF (2007) The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self. Semin Immunopathol 29:303–313PubMedCrossRef

15.

Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 416:603–607PubMedCrossRef

16.

Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med 202:1171–1177PubMedPubMedCentralCrossRef

17.

Kawasaki T, Kawai T, Akira S (2011) Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev 243:61–73PubMedCrossRef

18.

Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A (2003) Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837–847PubMedCrossRef

19.

Xie H, Kong X, Zhou H, Xie Y, Sheng L, Wang T, Xia L, Yan J (2015) TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome. Clin Immunol 160:198–210PubMedCrossRef

20.

Cheng S, Wang H, Zhou H (2016) The role of TLR4 on B cell activation and anti-β(2)GPI antibody production in the antiphospholipid syndrome. J Immunol Res 2016:1719720PubMedPubMedCentralCrossRef

21.

Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710PubMedPubMedCentralCrossRef

22.

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747–1756PubMedPubMedCentralCrossRef

23.

Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192:1453–1466PubMedPubMedCentralCrossRef

24.

Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30:576–587PubMedPubMedCentralCrossRef

25.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170–1178PubMedCrossRef

26.

Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN (2012) A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 150:1235–1248PubMedPubMedCentralCrossRef

27.

Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky JA, Nir-Paz R, Paul WE (2013) IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 210:491–502PubMedPubMedCentralCrossRef

28.

Lowenthal JW, Cerottini JC, MacDonald HR (1986) Interleukin 1-dependent induction of both interleukin 2 secretion and interleukin 2 receptor expression by thymoma cells. J Immunol 137:1226–1231PubMed

29.

Koyama N, Harada N, Takahashi T, Mita S, Okamura H, Tominaga A, Takatsu K (1988) Role of recombinant interleukin-1 compared to recombinant T-cell replacing factor/interleukin-5 in B-cell differentiation. Immunology 63:277–283PubMedPubMedCentral

30.

Shin MS, Kang Y, Lee N, Wahl ER, Kim SH, Kang KS, Lazova R, Kang I (2013) Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol 190:1407–1415PubMedPubMedCentralCrossRef

31.

Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33:2398–2340PubMed

32.

Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731–734PubMedCrossRef

33.

Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L (2012) Blau syndrome, clinical and genetic aspects. Autoimmun Rev 12:44–51PubMedCrossRef

34.

Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM, Sfriso P, Verrecchia E, Tognon S, Bascherini V, Galeazzi M, Punzi L, Cantarini L (2014) Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 13:1220–1229PubMedCrossRef

35.

Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG, Girardin SE (2007) The nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol 29:289–301PubMedCrossRef

36.

Caso F, Wouters CH, Rose CD, Costa L, Tognon S, Sfriso P, Cantarini L, Rigante D, Punzi L (2014) Blau syndrome and latent tubercular infection: an unresolved partnership. Int J Rheum Dis 17:586–587PubMed

37.

Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33:1–9PubMed

38.

Shin MS, Kang Y, Lee N, Kim SH, Kang KS, Lazova R, Kang I (2012) U1-small nuclear ribonucleoprotein activates the NLRP3 inflammasome in human monocytes. J Immunol 188:4769–4775PubMedPubMedCentralCrossRef

39.

Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ (2011) Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 187:6143–6156PubMedPubMedCentralCrossRef

40.

Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, Köhl J, Cook HT, Kemper C (2013) C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122:3473–3481PubMedCrossRef

41.

Hui Z, Rong F, Chaohuan G, Yuefang H, Hongyue W, Shuang W, Jijun Z, Niansheng Y (2016) Anti-dsDNA antibodies bind to TLR4 and activate NLRP3 inflammasome in lupus monocytes/macrophages. J Transl Med 14:156CrossRef

42.

Rong F, Chaohuan G, Shuang W, Yuefang H, Ou J, Haoqiang H, Jingxian C, Bihua X, Mianjing Z, Jijun Z, Sun-sang J, Hongyang W, Felicia G, Niansheng Y, Shu Man F (2017) Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol 69:1636–1646

43.

Caso F, Cantarini L, Lucherini OM, Sfriso P, Fioretti M, Costa L, Vitale A, Atteno M, Galeazzi M, Muscari I, Magnotti F, Frediani B, Punzi L, Rigante D (2014) Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol 24:381–389PubMedCrossRef

44.

Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, Compagnone A, Caso P, Frediani B, Galeazzi M, Punzi L, Cantarini L (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013:513782PubMedPubMedCentralCrossRef

45.

Llndor NM, Arsenault TM, Solomon H, Seidman CE, McEvov MT (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611–615CrossRef

46.

Hutton HL, Ooi JD, Holdsworth SR, Kitching AR (2016) The NLRP3 inflammasome in kidney disease and autoimmunity. Nephrology (Carlton) 21:736–744CrossRef

47.

Majeed HA, Kalaawi M, Mohanty D, Teebi AS, Tunjekar MF, al-Gharbawy F, Majeed SA, al-Gazzar AH (1989) Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 115:730–734PubMedCrossRef

48.

Herlin T, Fiirgaard B, Bjerre M, Kerndrup G, Hasle H, Bing X, Ferguson PJ (2013) Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 72:410–413PubMedCrossRef

49.

Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgård U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437PubMedPubMedCentralCrossRef

50.

Pathak S, McDermott MF, Savic S (2017) Autoinflammatory diseases: update on classification diagnosis and management. J Clin Pathol 70:1–8PubMedCrossRef

51.

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920PubMedPubMedCentralCrossRef

52.

Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931PubMedCrossRef

53.

Lee-Kirsch MA, Wolf C, Kretschmer S, Roers A (2015) Type I interferonopathies—an expanding disease spectrum of immunodysregulation. Semin Immunopathol 37:349–357PubMedCrossRef

54.

Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M (2016) Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J 14:35PubMedPubMedCentralCrossRef

55.

Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, Artuch R, Montalto SA, Bacino CA, Barroso B, Baxter P, Benko WS, Bergmann C, Bertini E, Biancheri R, Blair EM, Blau N, Bonthron DT, Briggs T, Brueton LA, Brunner HG, Burke CJ, Carr IM, Carvalho DR, Chandler KE, Christen HJ, Corry PC, Cowan FM, Cox H, D'Arrigo S, Dean J, De Laet C, De Praeter C, Dery C, Ferrie CD, Flintoff K, Frints SG, Garcia-Cazorla A, Gener B, Goizet C, Goutieres F, Green AJ, Guet A, Hamel BC, Hayward BE, Heiberg A, Hennekam RC, Husson M, Jackson AP, Jayatunga R, Jiang YH, Kant SG, Kao A, King MD, Kingston HM, Klepper J, van der Knaap MS, Kornberg AJ, Kotzot D, Kratzer W, Lacombe D, Lagae L, Landrieu PG, Lanzi G, Leitch A, Lim MJ, Livingston JH, Lourenco CM, Lyall EG, Lynch SA, Lyons MJ, Marom D, McClure JP, McWilliam R, Melancon SB, Mewasingh LD, Moutard ML, Nischal KK, Ostergaard JR, Prendiville J, Rasmussen M, Rogers RC, Roland D, Rosser EM, Rostasy K, Roubertie A, Sanchis A, Schiffmann R, Scholl-Burgi S, Seal S, Shalev SA, Corcoles CS, Sinha GP, Soler D, Spiegel R, Stephenson JB, Tacke U, Tan TY, Till M, Tolmie JL, Tomlin P, Vagnarelli F, Valente EM, Van Coster RN, Van der Aa N, Vanderver A, Vles JS, Voit T, Wassmer E, Weschke B, Whiteford ML, Willemsen MA, Zankl A, Zuberi SM, Orcesi S, Fazzi E, Lebon P, Crow YJ (2007) Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 81:713–725PubMedPubMedCentralCrossRef

56.

Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, Martínez de Villarreal L, dos Santos HG, Garg A (2010) PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 87:866–872PubMedPubMedCentralCrossRef

57.

Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, Toyoshima Y, Takahashi H, Standley DM, Tanaka K, Hamazaki J, Murata S, Obara K, Toyoshima I, Yasutomo K (2011) A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 121:4150–4160PubMedPubMedCentralCrossRef

58.

Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee CC, Chen Y, Vera A, Zhang X, Goldbach-Mansky R, Zlotogorski A (2012) Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64:895–907PubMedPubMedCentralCrossRef

59.

Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendínez F, Hernández A, López-Robledillo JC, Dadban A, Requena L, Paller AS (2010) Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol 62:489–495PubMedCrossRef

60.

Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, Overton J, Meffre E, Khokha MK, Huttner AJ, West B, Podoltsev NA, Boggon TJ, Kazmierczak BI, Lifton RP (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46:1135–1139PubMedPubMedCentralCrossRef

61.

Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, DiMattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O'Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146PubMedPubMedCentralCrossRef

62.

Zhao Y, Shao F (2015) The NAIP-NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus. Immunol Rev 265:85–102PubMedCrossRef

63.

Kofoed EM, Vance RE (2012) NAIPs: building an innate immune barrier against bacterial pathogens. NAIPs function as sensors that initiate innate immunity by detection of bacterial proteins in the host cell cytosol. Bioessays 34:589–598PubMedCrossRef

64.

Cush JJ (2013) Autoinflammatory syndromes. Dermatol Clin 31:471–480PubMedPubMedCentralCrossRef

65.

Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD (2008) Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 4:e1000024PubMedPubMedCentralCrossRef

66.

Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC Jr, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S (2004) Gene map of the extended human MHC. Nat Rev Genet 5:889–899PubMedCrossRef

67.

Sollid LM, Pos W, Wucherpfennig KW (2014) Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr Opin Immunol 31:24–30PubMedCrossRef

68.

Morris DL, Taylor KE, Fernando MM, Nititham J, Alarcón-Riquelme ME, Barcellos LF, Behrens TW, Cotsapas C, Gaffney PM, Graham RR, Pons-Estel BA, Gregersen PK, Harley JB, Hauser SL, Hom G, International MHC and Autoimmunity Genetics Network, Langefeld CD, Noble JA, Rioux JD, Seldin MF, Systemic Lupus Erythematosus Genetics Consortium, Criswell LA, Vyse TJ (2012) Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet 91:778–793PubMedPubMedCentralCrossRef

69.

Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D, Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA, Wellcome Trust Case Control Consortium (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887–892PubMedPubMedCentralCrossRef

70.

Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, Raj T, IMSGC.; ANZgene, Gourraud PA, Stranger BE, Oksenberg J, Olsson T, Taylor BV, Sawcer S, Hafler DA, Carrington M, De Jager PL, de Bakker PI (2013) Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet e1003926:9

71.

Björck S, Brundin C, Lörinc E, Lynch KF, Agardh D (2010) Screening detects a high proportion of celiac disease in young HLA-genotyped children. J Pediatr Gastroenterol Nutr 50:49–53PubMedCrossRef

72.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedPubMedCentralCrossRef

73.

Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessière C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594PubMed

74.

Moeez S, John P, Bhatti A (2013) Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool. Rheumatol Int 33:1669–1673PubMedCrossRef

75.

Klareskog L, Padyukov L, Rönnelid J, Alfredsson L (2006) Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 18:650–655PubMedCrossRef

76.

van Lummel M, Duinkerken G, van Veelen PA, de Ru A, Cordfunke R, Zaldumbide A, Gomez-Touriño I, Arif S, Peakman M, Drijfhout JW, Roep BO (2014) Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 63:237–247PubMedCrossRef

77.

Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, Ustek D, Satorius C, Ueda A, Takeno M, Kim Y, Wood GM, Ombrello MJ, Meguro A, Gül A, Remmers EF, Kastner DL (2013) Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45:202–207PubMedPubMedCentralCrossRef

78.

Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, Spondyloarthritis Research Consortium of Canada (SPARCC), Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Díaz-Peña R, López-Vázquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, McCann OT, McCarthy MI, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P, Australo-Anglo-American Spondyloarthritis Consortium (TASC); Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43:761–767PubMedPubMedCentralCrossRef

79.

Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, Siminovitch KA, Bae SC, Plenge RM, Gregersen PK, de Bakker PI (2012) Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44:291–296PubMedPubMedCentralCrossRef

80.

Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Ståhle M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J, Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J, Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2, Nair RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath RC (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44:1341–1348PubMedPubMedCentralCrossRef

81.

McGonagle D, Aziz A, Dickie LJ, McDermott MF (2009) An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 65:38R–45RPubMedCrossRef

82.

Mohan VK, Ganesan N, Gopalakrishnan R (2014) Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis. J Genet 93:597–605PubMedCrossRef

83.

Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, International Inflammatory Bowel Disease Genetics Consortium, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW et al (2016) Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387:156–167PubMedPubMedCentralCrossRef

84.

Moroldo MB, Donnelly P, Saunders J, Glass DN, Giannini EH (1998) Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 41:1620–1624PubMedCrossRef

85.

Rossi-Semerano L, Koné-Paut I (2012) Is Still’s disease an autoinflammatory syndrome? Int J Inflamm 2012:480373CrossRef

86.

Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedCrossRef

87.

Lebowitz MS, O'Herrin SM, Hamad AR, Fahmy T, Marguet D, Barnes NC, Pardoll D, Bieler JG, Schneck JP (1999) Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol 192:175–184PubMedCrossRef

88.

Novak EJ, Liu AW, Nepom GT, Kwok WW (1999) MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 104:R63–R67PubMedPubMedCentralCrossRef

89.

Klein L, Kyewski B, Allen PM, Hogquist KA (2014) Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 14:377–391PubMedPubMedCentralCrossRef

90.

Andrade LE (2009) Future perspective for diagnosis in autoimmune diseases. An Acad Bras Cienc 81:367–380PubMedCrossRef

91.

Worth A, Thrasher AJ, Gaspar HB (2006) Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133:124–140PubMedCrossRef

92.

Beretta L, Cappiello F, Barili M, Bertolotti F, Scorza R (2007) T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol 26:88–91PubMedCrossRef

93.

Yang CA, Chiang BL (2015) Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun 61:1–8PubMedCrossRef

94.

dos Santos BP, Valverde JV, Rohr P, Monticielo OA, Brenol JC, Xavier RM, Chies JA (2012) TLR7/8/9 polymorphisms and their associations in systemic lupus erythematosus patients from southern Brazil. Lupus 21:302–309PubMedCrossRef

95.

Zhang J, Zhu Q, Meng F, Lei H, Zhao Y (2014) Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. Gene 533:385–388PubMedCrossRef

96.

Huang CM, Huang PH, Chen CL, Lin YJ, Tsai CH, Huang WL, Tsai FJ (2012) Association of toll-like receptor 9 gene polymorphism in Chinese patients with systemic lupus erythematosus in Taiwan. Rheumatol Int 32:2105–2109PubMedCrossRef

97.

Piotrowski P, Lianeri M, Wudarski M, Olesińska M, Jagodziński PP (2013) Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus. Rheumatol Int 33:1121–1125PubMedCrossRef

98.

Oyanguren-Desez O, Rodríguez-Antigüedad A, Villoslada P, Domercq M, Alberdi E, Matute C (2011) Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium 50:468–472PubMedCrossRef

99.

Chen S, Sun B (2013) Negative regulation of NLRP3 inflammasome signaling. Protein Cell 4:251–258PubMedPubMedCentralCrossRef

100.

Haneklaus M, O'Neill LA, Coll RC (2013) Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 25:40–45PubMedCrossRef

101.

Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216–1225PubMedCrossRef

102.

Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Söderkvist P (2008) Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 47:415–417CrossRef

103.

Yang CA, Huang ST, Chiang BL (2014) Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population. Scand J Rheumatol 43:146–152PubMedCrossRef

104.

Yang CA, Huang ST, Chiang BL (2015) Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages. Rheumatology (Oxford) 54:324–331CrossRef

105.

Maggadottir SM, Sullivan KE (2014) The intersection of immune deficiency and autoimmunity. Curr Opin Rheumatol 26:570–578PubMedCrossRef

106.

Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarström L, Nonoyama S, Notarangelo LD, Ochs HD, Puck JM, Roifman CM, Seger R, Tang ML (2011) Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2:54PubMedPubMedCentralCrossRef

107.

Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC (2003) Aire regulates negative selection of organ-specific T cells. Nat Immunol 4:350–354PubMedCrossRef

108.

Kisand K, Peterson P, Laan M (2014) Lymphopenia-induced proliferation in aire-deficient mice helps to explain their autoimmunity and differences from human patients. Front Immunol 5:51PubMedPubMedCentralCrossRef

109.

Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C, Ziegler SF, Levings MK, Roncarolo MG (2006) Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116:1713–1722PubMedPubMedCentralCrossRef

110.

Bonhomme D, Hammarström L, Webster D, Chapel H, Hermine O, Le Deist F, Lepage E, Romeo PH, Levy Y (2000) Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol 165:4725–4730PubMedCrossRef

111.

Warnatz K, Denz A, Dräger R, Braun M, Groth C, Wolff-Vorbeck G, Eibel H, Schlesier M, Peter HH (2002) Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99:1544–1551PubMedCrossRef

112.

Sánchez-Ramón S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C (2008) Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 128:314–321PubMedPubMedCentralCrossRef

113.

Notarangelo LD, Miao CH, Ochs HD (2008) Wiskott-Aldrich syndrome. Curr Opin Hematol 15:30–36PubMedCrossRef

114.

Castiello MC, Bosticardo M, Pala F, Catucci M, Chamberlain N, van Zelm MC, Driessen GJ, Pac M, Bernatowska E, Scaramuzza S, Aiuti A, Sauer AV, Traggiai E, Meffre E, Villa A, van der Burg M (2014) Wiskott-Aldrich syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J Autoimmun 50:42–50PubMedPubMedCentralCrossRef

115.

Westerberg LS, Klein C, Snapper SB (2008) Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency—lessons learned from monogenic disorders in mice and men. Curr Opin Immunol 20:646–654PubMedPubMedCentralCrossRef

116.

Cravens PD, Lipsky PE (2002) Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 80:497–505PubMedCrossRef

117.

Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMedCrossRef

118.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252PubMedCrossRef

119.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRef

120.

Ludewig B, Junt T, Hengartner H, Zinkernagel RM (2001) Dendritic cells in autoimmune diseases. Curr Opin Immunol 13:657–662PubMedCrossRef

121.

Corti D, Sallusto F, Lanzavecchia A (2011) High throughput cellular screens to interrogate the human T and B cell repertoires. Curr Opin Immunol 23:430–435PubMedCrossRef

122.

Leyendeckers H, Odendahl M, Löhndorf A, Irsch J, Spangfort M, Miltenyi S, Hunzelmann N, Assenmacher M, Radbruch A, Schmitz J (1999) Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 29:1406–1417PubMedCrossRef

123.

Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H, Busch DH (2007) A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27:985–997PubMedCrossRef

124.

Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915PubMedCrossRef

125.

Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A (2012) Integration of B cell responses through toll-like receptors and antigen receptors. Nat Rev Immunol 12:282–294PubMedPubMedCentralCrossRef

126.

Leadbetter EA, Rifkin IR, Marshak-Rothstein A (2003) Toll-like receptors and activation of autoreactive B cells. Curr Dir Autoimmun 6:105–122PubMedCrossRef

127.

Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF (2007) TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178:2415–2420PubMedCrossRef

128.

Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182:7459–7472PubMedPubMedCentralCrossRef

129.

Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL (2011) Selective utilization of toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34:375–384PubMedPubMedCentralCrossRef

130.

Suurmond J, Diamond B (2015) Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest 125:2194–2202PubMedPubMedCentralCrossRef

131.

Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV (2006) TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 203:553–561PubMedPubMedCentralCrossRef

132.

Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417–428PubMedCrossRef

133.

Hua Z, Gross AJ, Lamagna C, Ramos-Hernández N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL (2014) Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 192:875–885PubMedCrossRef

134.

Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, Smyth MJ, Mackay CR, Mackay F (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959–1971PubMedPubMedCentralCrossRef

135.

Suurmond J, Rivellese F, Dorjée AL, Bakker AM, Rombouts YJ, Rispens T, Wolbink G, Zaldumbide A, Hoeben RC, Huizinga TW, Toes RE (2015) Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis 74:1915–1923PubMedCrossRef

136.

Pitzalis C, Jones GW, Bombardieri M, Jones SA (2014) Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 14:447–462PubMedCrossRef

137.

Thapa DR, Tonikian R, Sun C, Liu M, Dearth A, Petri M, Pepin F, Emerson RO, Ranger A (2015) Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing. Arthritis Res Ther 17:132PubMedPubMedCentralCrossRef

138.

Attaf M, Huseby E, Sewell AK (2015) αβ T cell receptors as predictors of health and disease. Cell Mol Immunol 12:391–399PubMedPubMedCentralCrossRef

139.

Raulet DH (1989) The structure, function, and molecular genetics of the gamma/delta T cell receptor. Annu Rev Immunol 7:175–207PubMedCrossRef

140.

Chothia C, Boswell DR, Lesk AM (1988) The outline structure of the T-cell alpha beta receptor. EMBO J 7:3745–3755PubMedPubMedCentralCrossRef

141.

Alam SM, Davies GM, Lin CM, Zal T, Nasholds W, Jameson SC, Hogquist KA, Gascoigne NR, Travers PJ (1999) Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity 10:227–237PubMedCrossRef

142.

Almeida A, Rocha B, Freitas AA, Tanchot C (2005) Homeostasis of T cell numbers: from thymus production to peripheral compartmentalization and the indexation of regulatory T cells. Semin Immunol 17:239–249PubMedCrossRef

143.

Takeuchi T, Abe T, Koide J, Hosono O, Morimoto C, Homma M (1984) Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. Arthritis Rheum 27:766–773PubMedCrossRef

144.

Datta SK, Kaliyaperumal A, Mohan C, Desai-Mehta A (1997) T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Lupus 6:333–336PubMedCrossRef

145.

Shivakumar S, Tsokos GC, Datta SK (1989) T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143:103–112PubMed

146.

Shlomchik M, Mascelli M, Shan H, Radic MZ, Pisetsky D, Marshak-Rothstein A, Weigert M (1990) Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 171:265–292PubMedCrossRef

147.

Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK (1995) Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 95:531–541PubMedPubMedCentralCrossRef

148.

Luo W, Ma L, Wen Q, Wang N, Zhou MQ, Wang XN (2008) Analysis of the interindividual conservation of T cell receptor alpha- and beta-chain variable regions gene in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 154:316–324PubMedPubMedCentralCrossRef

149.

Winchester R, Wiesendanger M, Zhang HZ, Steshenko V, Peterson K, Geraldino-Pardilla L, Ruiz-Vazquez E, D'Agati V (2012) Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8+ T cell β-chain clonotypes in progressive lupus nephritis. Arthritis Rheum 64:1589–1600PubMedPubMedCentralCrossRef

150.

Yin Y, Choi SC, Xu Z, Perry DJ, Seay H, Croker BP, Sobel ES, Brusko TM, Morel L (2015) Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med 7:274ra18PubMedPubMedCentralCrossRef

151.

Pearce EL, Poffenberger MC, Chang CH, Jones RG (2013) Fueling immunity: insights into metabolism and lymphocyte function. Science 342:1242454PubMedPubMedCentralCrossRef

152.

Diveu C, McGeachy MJ, Cua DJ (2008) Cytokines that regulate autoimmunity. Curr Opin Immunol 20:663–668PubMedCrossRef

153.

Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849–1861PubMedPubMedCentralCrossRef

154.

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedPubMedCentralCrossRef

155.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133PubMedCrossRef

156.

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950–957PubMedCrossRef

157.

Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279PubMedPubMedCentralCrossRef

158.

Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–1132PubMedCrossRef

159.

Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141PubMedPubMedCentralCrossRef

160.

Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F (2012) Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484:514–518PubMedCrossRef

161.

Noster R, de Koning HD, Maier E, Prelog M, Lainka E, Zielinski CE (2016) Dysregulation of proinflammatory versus anti-inflammatory human T(H)17 cell functionalities in the autoinflammatory Schnitzler syndrome. J Allergy Clin Immunol 138:1161–1169.e6PubMedCrossRef

162.

Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189PubMedCrossRef

163.

Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5–7PubMed

164.

Chevalier N, Thorburn AN, Macia L, Tan J, Juglair L, Yagita H, Yu D, Hansbro PM, Mackay CR (2014) Inflammation and lymphopenia trigger autoimmunity by suppression of IL-2-controlled regulatory T cell and increase of IL-21-mediated effector T cell expansion. J Immunol 193:4845–4858PubMedCrossRef

165.

Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:62–68PubMedCrossRef

166.

Kuhn A, Beissert S, Krammer PH (2009) CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 301:71–81PubMedCrossRef

167.

Sakaguchi S, Sakaguchi N (2005) Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 24:211–226PubMedCrossRef

168.

Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef

169.

Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32PubMedCrossRef

170.

Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400PubMedCrossRef

171.

Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E (2007) Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 16:489–496PubMedCrossRef

172.

Cao D, Malmström V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C (2003) Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 33:215–223PubMedCrossRef

173.

Ballanti E, Perricone C, Greco E, Ballanti M, Di Muzio G, Chimenti MS, Perricone R (2013) Complement and autoimmunity. Immunol Res 56:477–491PubMedCrossRef

174.

Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM (2005) Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 97:171–179PubMedCrossRef

175.

Nauta AJ, Roos A, Daha MR (2004) A regulatory role for complement in innate immunity and autoimmunity. Int Arch Allergy Immunol 134:310–323PubMedCrossRef

176.

Morgan BP, Harris CL (2003) Complement therapeutics; history and current progress. Mol Immunol 40:159–170PubMedCrossRef

177.

Avery TY, van de Cruys M, Austen J, Stals F, Damoiseaux JG (2014) Anti-nuclear antibodies in daily clinical practice: prevalence in primary, secondary, and tertiary care. J Immunol Res 2014:401739PubMedPubMedCentralCrossRef

178.

Kumar Y, Bhatia A, Minz RW (2009) Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 4:1PubMedPubMedCentralCrossRef

179.

Kovarik J (2013) From immunosuppression to immunomodulation: current principles and future strategies. Pathobiology 80:275–281PubMedCrossRef

180.

Baker KF, Isaacs JD (2014) Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol 26:219–227PubMedPubMedCentralCrossRef

181.

Löwenberg M, Stahn C, Hommes DW, Buttgereit F (2008) Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73:1025–1029PubMedCrossRef

182.

Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–331PubMedCrossRef

183.

Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21:69–79PubMedCrossRef

184.

Akgul O, Kilic E, Kilic G, Ozgocmen S (2013) Efficacy and safety of biologic treatments in familial Mediterranean fever. Am J Med Sci 346:137–141PubMedCrossRef

185.

Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847CrossRef

186.

Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM, Sfriso P, Frediani B, Punzi L, Galeazzi M, Cimaz R, Obici L (2014) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum 43:818–823PubMedCrossRef

187.

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50:1445–1452CrossRef

188.

Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105:1133–1139PubMedCrossRef

189.

Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25:469–484PubMedPubMedCentralCrossRef

190.

Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D'Ascanio A, Carli L, Bombardieri S, LaSelva G, Iannone F, Lapadula G, Alivernini S, Ferraccioli G, Colaci M, Ferri C, Iacono D, Valentini G, Costa L, Scarpa R, LoMonaco A, Bagnari V, Govoni M, Piazza I, Adami S, Ciccia F, Triolo G, Alessandri E, Cutolo M, Cantarini L, Galeazzi M, Ruscitti P, Giacomelli R, Caso F, Galozzi P, Punzi L (2016) Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 35:1683–1689PubMedCrossRef

191.

Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I, Drewe E (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63:1151–1155PubMedCrossRef

192.

Fonseca JE, Santos MJ, Canhão H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542PubMedCrossRef

193.

Henrickson M, Wang H (2017) Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation. Clin Rheumatol 36:1445–1451PubMedPubMedCentralCrossRef

194.

Woodrick RS, Ruderman EM (2012) IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. Bull NYU Hosp Jt Dis 70:195–199PubMed

195.

Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediat Inflamm 2014:107421CrossRef

196.

Croft M, Siegel RM (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol 13:217–233PubMedPubMedCentralCrossRef

197.

Greco E, Aita A, Galozzi P, Gava A, Sfriso P, Negm OH, Tighe P, Caso F, Navaglia F, Dazzo E, De Bortoli M, Rampazzo A, Obici L, Donadei S, Merlini G, Plebani M, Todd I, Basso D, Punzi L (2015) The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway. Arthritis Res Ther 17:93PubMedPubMedCentralCrossRef

198.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838PubMedPubMedCentralCrossRef

199.

Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548–551PubMedCrossRef

200.

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef

201.

Andrade-Ortega L, Irazoque-Palazuelos F, Muñóz-López S, Rosales-Don Pablo VM (2013) Efficacy and tolerability of rituximab in patients with rhupus. Reumatol Clin 9:201–205PubMedCrossRef

202.

Caso F, Fiocco U, Costa L, Sfriso P, Punzi L, Doria A (2014) Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine 81:190–192PubMedCrossRef

203.

Shin JI, Eisenhut M (2014) A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion? J Allergy Clin Immunol 133:600PubMedCrossRef

204.

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349–356PubMedCrossRef

205.

Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB, PSUMMIT-1 and 2 Study Groups (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73:1000–1006PubMedPubMedCentralCrossRef

206.

Östör AJK (2008) Abatacept: a T-cell co- stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 28:1343–1353CrossRef

207.

Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM (2013) Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 14:2311–2313PubMedCrossRef

208.

Strand V, Kavanaugh AF (2004) The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford) 43:10–16

209.

Demidowich AP, Freeman AF, Kuhns DB, Aksentijevich I, Gallin JI, Turner ML, Kastner DL, Holland SM (2012) Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 64:2022–2027PubMedCrossRef

210.

Nepom GT (2012) MHC class II tetramers. J Immunol 188:2477–2482PubMedPubMedCentralCrossRef

211.

Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I (1983) The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell 35:295–302PubMedCrossRef

212.

Damoiseaux JG, Tervaert JW (2006) From ANA to ENA: how to proceed? Autoimmun Rev 5:10–17PubMedCrossRef

213.

Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, Wilson MR, Fritzler M, IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases (2004) Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum 51:291–298PubMedCrossRef

214.

Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A (2013) Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 56:390–397PubMedCrossRef

215.

Arakelyan A, Nersisyan L, Poghosyan D, Khondkaryan L, Hakobyan A, Löffler-Wirth H, Melanitou E, Binder H (2017) Autoimmunity and autoinflammation: a systems view on signaling pathway dysregulation profiles. PLoS One 12:e0187572PubMedPubMedCentralCrossRef

Springer Medizin

From autoinflammation to autoimmunity: old and recent findings

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Correction to: The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink

Medicaid or Medicare insurance payer status and household income are associated with outcomes after primary total hip arthroplasty

Running does not increase symptoms or structural progression in people with knee osteoarthritis: data from the osteoarthritis initiative

Correction to: Musculoskeletal infections caused by Aerococcus urinae: a case-based review

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study